New technique could be used to choose best therapies for patients and measure their effectiveness
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
Scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer’s and Huntington’s disease. Their goal was to find molecular patterns specific to these diseases.
The algorithm was able to detect how these patients’ genes expressed themselves in unique ways over decades. This offers the first long-term view of molecular changes underlying neurodegeneration, an important accomplishment because neurodegenerative diseases develop over years.
Previous studies of neurodegeneration often used static or “snapshot” data, and are therefore limited in how much they can reveal about the typically slow progression of disease. This study aimed to uncover the chronological information contained in large-scale data by covering decades of disease progression, revealing how changes in gene expression over that time are related to changes in the patient’s condition.
Furthermore, the blood test detected 85 to 90 per cent of the top predictive molecular pathways that the test of post-mortem brain data did, showing a striking similarity between molecular alterations in both the brain and peripheral body.
“This test could one day be used by doctors to evaluate patients and prescribe therapies tailored to their needs,” says Yasser Iturria-Medina, the study’s first author. “It could also be used in clinical trials to categorize patients and better determine how experimental drugs impact their predicted disease progression.”
Iturria-Medina says his next steps will be testing these models in other diseases such as Parkinson’s disease and amyotrophic lateral sclerosis.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
AI-analyzed blood test
- Blood test powered by AI could catch osteoarthritis 8 years earlier than X-ray, early data show
A new blood test could determine whether someone will develop knee osteoarthritis up to eight years before structural damage is picked up by an X-ray.
- OMI AI Model: The Dawn of a New Era in Emergency Cardiac Diagnosis
In the fast-paced environment of emergency departments across Europe and the United States, where over 50 million individuals annually report chest pain, the precision of early diagnostics of Acute ...
- The $10,000-a-Month ‘Wellness Social Club’ on Greenwich Street
Using AI and a little bit of your blood, Continuum Club promises a “journey to becoming the ideal version of oneself.” ...
- AI Model Predicts Inpatient Hypoglycemic Events
Researchers demonstrated the model's excellent performance, raising hopes that it can someday prove a valuable tool for reducing such events in hospitalized patients.
- AI and the Constitution: How Technology Challenges Legal Protections
The Fourth and Sixth Amendments present contexts where the legal profession will continue to grapple with the blurred line between human and machine. These amendments, respectively, protect the rights ...
Go deeper with Google Headlines on:
AI-analyzed blood test
[google_news title=”” keyword=”AI-analyzed blood test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Neurodegenerative disease
- Decoding Parkinson’s disease: New genetic variant offers hope for future treatments
Researchers have discovered a new genetic variant, RAB32 Ser71Arg, linked to Parkinson's disease across several countries. This variant interacts with proteins affecting dopamine levels and cell ...
- Synthetic nanomaterial could be an effective tool for treating neurodegenerative diseases
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases.
- NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. NKGen is headquartered in Santa ...
- Nanomaterial that mimics proteins could be basis for new neurodegenerative disease treatments
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases. The nanomaterial alters the interaction ...
- Neurons re-entering cell cycle succumb to senescence in neurodegenerative diseases
Post-mitotic neurons in the brain that re-enter the cell cycle quickly succumb to senescence, and this re-entry is more common in Alzheimer's disease, according to a new study published April 9th in ...
Go deeper with Google Headlines on:
Neurodegenerative disease
[google_news title=”” keyword=”neurodegenerative disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]